Gate2Brain technology seeks to increase the effectiveness and reduce the side effects of treatments for brain disease.
It is based on a research line developed at IRB Barcelona and breakthroughs made jointly with the University of Barcelona and the Sant Joan de Déu Research Institute - Hospital Sant Joan de Déu.
The company has been launched with the support of the Mind the Gap Programme run by the Botín Foundation, which will provide an initial investment of €500,000 and management support through an expert advisor.
Ona Therapeutics, a spin-off from IRB Barcelona and ICREA, was founded by researchers Salvador Aznar-Benitah and Valerie Vanhooren in 2019. The company focuses its activity on the development of a new medicine for the treatment of metastatic cancer.
The venture capital funding round has been headed by Asabys Partners, through its Sabadell Asabys division, and has involved the participation of Alta Life Sciences, Ysios Capital, FundPlus (Belgium) and BPI France (France)
This is the largest private funding round closed for a start-up in Spain.
Iproteos, one of the 5 spin-offs launched by IRB Barcelona, focuses on the development of third-generation drugs for diseases such as schizophrenia, epilepsy, and atherosclerosis.
Its proprietary technology allows faster research processes to identify new drugs and produce novel molecules.
The new company Accure Therapeutics starts up with €7.6 M of investment, which will allow the development of its product portfolio and the takeover of Iproteos and Bionure.
The Center for Genomic Regulation (CRG), the National Center for Genomic Analysis (CNAG-CRG), part of CRG, the Institute for Research in Biomedicine (IRB Barcelona) and the Institute for Bioengineering of Catalonia (IBEC) have analysed more than 20,000 samples to date using the PCR technique. In this regard, 17,547 samples have been tested at the CRG node and 5,248 at the PCB node.
The analyses are part of the Orfeu Programme, the mass screening initiative driven by the Government of Catalonia. As of today, the public health system in Catalonia can carry out up to 17,000 PCR tests every day. This number does not include the capacity of the Orfeu Programme, which can process up to...
The global pandemic that we are living poses a major challenge for society at all levels. In these moments of uncertainty, IRB Barcelona has put what it knows best, cutting-edge research, at the service of the public.
IRB Barcelona’s efforts are focused on two lines of action. The first is participation in the mass PCR-based screening initiative of the Orfeu Programme, driven by the Government of Catalonia, in collaboration with the research centres CRG, IBEC and CNAG.
The second line of action is the research...
Committed to fostering gender equality policies, IRB Barcelona participates in the EU-funded CALIPER to implement a Gender Equality Plan and thus fulfil gender mainstreaming as a strategy of organisational development.
In order to prevent gender discrimination in scientific institutions, CALIPER aims to promote a universal methodology that provides permanent support for gender equality.
The ALBA Synchrotron will host two new major experimental facilities, one dedicated to materials science, valued at 4.1 million euros and led by the Catalan Institute of Nanoscience and Nanotechnology (ICN2), and another meant for molecular biology, valued at 1.7 million euros and headed by the Institute of Molecular Biology of Barcelona (IBMB-CSIC).
The new platform also counts with the participation of the Barcelona Institute of Science and Technology (BIST), the Spanish Council for Scientific Research (CSIC), the Institute for Biomedical Research (IRB Barcelona), the Autonomous University of Barcelona (UAB), the Institute of Materials Science of Barcelona (ICMAB-CSIC) and the Centre for Genomic Regulation (CRG).
Today, the approval of the co-financing through the European Regional Development Fund (ERDF) of these two projects, which involve numerous institutions and research centres, has been made public.
Against the backdrop of the current health crisis, IRB Barcelona has been following the directives of the authorities to guarantee the health of its employees, to contribute to preventive measures to stop the spread of COVID-19, and to minimize the impact of these measures on the lines of research undertaken at the Institute. The aim is to guarantee minimum services and the maintenance of the Institute's research facilities and tools.
The work done by our computational scientists and many of the lab and administration tasks will continue to be undertaken. However, some projects have inevitably been suspended until things get back to normal and we can return to work. IRB Barcelona...